Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma

Leanne Kaye; Vy Vuong; Meredith Barrett; Elroy Boers; Theresa W. Guilbert

doi:10.1038/s41533-022-00299-3

September 2, 2022npj Primary Care Respiratory MedicineOpen Access

Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Significant indirect healthcare costs are related to uncontrolled asthma, including productivity loss. Days with short-acting beta-agonist (SABA) use is associated with symptom-related disruptions at work, home, and school. Digital self-management platforms may support fewer days with SABA medication use and may reduce symptom-related disruptions.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kaye et al. (2022) studied this question.

synapsesocial.com/papers/6a7f3475b6d9438a3a6a7cb8 https://doi.org/10.1038/s41533-022-00299-3

View Full Paper

Ask AI

Bookmark

Share

Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma

Ask about this paper

Abstract

Discussion

Cite This Study

Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading